转移灶定向外照射联合177Lu-PSMA-617治疗晚期去势抵抗性前列腺癌
该回顾性多机构研究分析了261例接受LuPSMA治疗的患者,其中52例同期接受转移灶定向外照射(M-EBRT)。M-EBRT主要用于颅内/硬膜外病变、骨痛姑息和预防病理性骨折,多数患者症状缓解且耐受性良好,但淋巴细胞减少常见。
要点
- 52例同期接受M-EBRT,主要适应证为颅内/硬膜外病变(42%)、骨痛姑息(33%)和预防病理性骨折(23%)。
- 62%的患者M-EBRT后症状缓解,总体耐受性良好,但淋巴细胞减少常见。
- M-EBRT前、中、后给药组症状缓解率分别为68%、85%、50%,死亡率分别为32%、29%、57%,差异无统计学意义(P > .23)。
核心结论
- 在此经验中,M-EBRT与LuPSMA联合用于局部肿瘤控制和症状管理有效,尤其对局限性骨和中枢神经系统病变,且耐受性良好。
- M-EBRT可能是促进LuPSMA启动和/或继续的重要辅助治疗方式。
研究设计与样本
- 回顾性、机构审查委员会豁免的多机构学术癌症中心研究,审查FDA批准后前2年内接受LuPSMA治疗的患者。
- 共审查261例接受LuPSMA治疗的患者,其中52例同期接受M-EBRT。
主要发现
- M-EBRT适应证:颅内/硬膜外病变22/52(42%),骨痛姑息17/52(33%),预防病理性骨折12/52(23%),其他适应证6/52(12%)。
- M-EBRT时机:54%(28/52)在LuPSMA前,27%(14/52)在LuPSMA后,13%(7/52)在LuPSMA期间。
- 大多数患者(32/52;62%)M-EBRT后症状缓解。
- M-EBRT前、中、后给药组症状缓解率分别为68%、85%、50%,死亡率分别为32%、29%、57%,差异无统计学意义(P > .23)。
- 该人群PSA50应答率为41%,一般LuPSMA人群为50%,但PSA应答幅度异质(P = .27)。
临床怎么用
- M-EBRT可用于接受LuPSMA患者的局部肿瘤控制和症状管理,尤其针对局限性骨和中枢神经系统病变。
- M-EBRT耐受性良好,但需注意淋巴细胞减少。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 177Lu-PSMA-617 (LuPSMA) is an effective radiopharmaceutical therapy for patients with metastatic castration-resistant prostate cancer. While LuPSMA can treat disseminated disease, additional localized control of metastatic disease may be required. Metastasis-targeted external beam radiation therapy (M-EBRT) can be an effective adjunct. However, the indications, efficacy, and safety/toxicity of combining M-EBRT with LuPSMA are unclear. Here, we report our experience with M-EBRT in patients receiving LuPSMA and assess M-EBRT's ability for local disease control and palliation. METHODS AND MATERIALS: This retrospective institutional review board-exempted study reviewed patients treated with LuPSMA at a multi-institutional academic cancer center within the first 2 years after United States Food and Drug Administration's approval, receiving contemporaneous M-EBRT. Clinical factors driving the use of M-EBRT were analyzed. RESULTS: Treatment courses of 261 patients receiving LuPSMA were reviewed; 52 patients received M-EBRT contemporaneously. M-EBRT was administered for intracranial/epidural disease (n = 22/52; 42%), bone pain palliation (n = 17/52; 33%), prevention of pathological fractures (n = 12/52; 23%), and 12% (n = 6/52) for various other indications. M-EBRT timing varied among patients, with 54% (n = 28/52) receiving M-EBRT before, 27% (n = 14/52) after, and 13% (n = 7/52) during LuPSMA therapy. EBRT was mostly well tolerated, although lymphopenia was commonly experienced. Most patients (n = 32/52; 62%) had symptom relief following M-EBRT. Symptom relief post-M-EBRT was 68%, 85%, and 50%, and mortality rates were 32%, 29%, and 57% for patients receiving EBRT before, during, and after LuPSMA treatment, respectively, albeit not statistically significant (P > .23). Prostate-specific antigen (PSA)50 (decrease in PSA by 50% during treatment) response in this patient population was 41% compared with 50% in the general LuPSMA population, but the magnitude of PSA response was heterogeneous (P = .27). CONCLUSIONS: In our experience, M-EBRT was used effectively with LuPSMA therapy for local tumor control and symptom management, especially for localized osseous and central nervous system lesions, and with good tolerability. M-EBRT may be an important adjunct treatment modality that facilitates the initiation and/or continuation of LuPSMA.
引用
- Mohammadi S, Pompa IR, Haberman V, et al. Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Pract Radiat Oncol. 2025. PMID: 40274261. doi:10.1016/j.prro.2025.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。